Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

BACKGROUND: A significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, CVID and AITP. Nonetheless, due to fewe...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheuerlein, Philipp, Pietsch, Larissa, Camacho-Ordonez, Nadezhda, Reiser, Veronika, Patel, Smita, Burns, Siobhan O., Warnatz, Klaus, Grimbacher, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060403/
https://www.ncbi.nlm.nih.gov/pubmed/30072997
http://dx.doi.org/10.3389/fimmu.2018.01656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060403/
https://www.ncbi.nlm.nih.gov/pubmed/30072997
http://dx.doi.org/10.3389/fimmu.2018.01656

Ejemplares similares